Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis.

TitleStaphylococcus aureus vaccine for orthopedic patients: an economic model and analysis.
Publication TypeJournal Article
Year of Publication2010
AuthorsLee BY, Wiringa AE, Bailey RR, G Lewis J, Feura J, Muder RR
JournalVaccine
Volume28
Issue12
Pagination2465-71
Date Published2010 Mar 11
ISSN1873-2518
KeywordsCost-Benefit Analysis, Humans, Methicillin-Resistant Staphylococcus aureus, Models, Statistical, Orthopedics, Preoperative Care, Staphylococcal Infections, Staphylococcal Vaccines, Surgical Wound Infection
Abstract

To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [or=30%, and a $100 vaccine at vaccine efficacy >or=70%. High MRSA prevalence (>or=25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.

DOI10.1016/j.vaccine.2009.12.075
Alternate JournalVaccine
PubMed ID20064479
PubMed Central IDPMC2833350
Grant List1U54GM088491-0109 / GM / NIGMS NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
U54 GM088491-01 / GM / NIGMS NIH HHS / United States
Publication Categories: